{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:23:48Z","timestamp":1790076228414,"version":"4.0.1"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Stenotrophomonas maltophilia<\/jats:named-content>\n            is increasingly being isolated from the respiratory tract of individuals with cystic fibrosis, and, because of its multidrug-resistant nature, the selection of suitable treatment regimens can be problematical. Etest methodology was used to facilitate MIC and antimicrobial combination testing on 80 isolates of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. maltophilia<\/jats:named-content>\n            cultured from the respiratory tract of Scottish individuals with cystic fibrosis between 2001 and 2010. The overall rate of susceptibility for the 1,410 MIC tests was 23.1%, and resistance was 68.9%. The most active antimicrobials were minocycline, co-trimoxazole, and doxycycline, with 92.4%, 87.3%, and 58.8% of isolates being susceptible, respectively. Of the 517 combinations, 13.2% were synergistic, with the most synergistic being ticarcillin\/clavulanate plus aztreonam (91.7% synergistic), ticarcillin\/clavulanate plus colistin (40%), and ticarcillin\/clavulanate plus levofloxacin (19.4%). Colistin plus tobramycin was the only antagonistic combination (0.2%). By the median susceptible breakpoint index, the most active combinations were minocycline plus co-trimoxazole (median index, 20), minocycline plus piperacillin-tazobactam (median, 20), and co-trimoxazole plus ceftazidime (median, 16.5). The increasing problem of multidrug resistance in organisms recovered from the respiratory tracts of individuals with cystic fibrosis is not going to go away. Current susceptibility testing methods do not address the slow-growing organisms associated with chronic infection, and interpretive standards are based on achievable blood levels of antimicrobials. Addressing these issues specifically for organisms recovered from the respiratory tracts of individuals with cystic fibrosis should lead to better therapeutic outcomes and improved wellbeing of individuals with cystic fibrosis.\n          <\/jats:p>","DOI":"10.1128\/aac.00072-12","type":"journal-article","created":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T05:40:21Z","timestamp":1337060421000},"page":"4071-4077","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":49,"title":["Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Stenotrophomonas maltophilia from Cystic Fibrosis Patients"],"prefix":"10.1128","volume":"56","author":[{"given":"K. E. N.","family":"Milne","sequence":"first","affiliation":[{"name":"Microbiology Department, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Gould","sequence":"additional","affiliation":[{"name":"Microbiology Department, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0732-8893(00)00163-2","article-title":"Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time kill and checkerboard methods","volume":"38","author":"Bonapace CR","year":"2000","unstructured":"BonapaceCR WhiteRL FriedrichLV BossoJA. 2000. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time kill and checkerboard methods. Diagn. Microbiol. Infect. Dis. 38:43\u201350.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/45.1.115","article-title":"Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates","volume":"45","author":"Bonfiglio G","year":"2000","unstructured":"BonfiglioG. 2000. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J. Antimicrob. Chemother. 45:115\u2013117.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"ChandraS. 2008. Stenotrophomonas maltophilia in cystic fibrosis. Chest 134(Suppl.):S57002. http:\/\/meeting.chestpubs.org\/cgi\/content\/abstract\/134\/4\/s57002.","DOI":"10.1378\/chest.134.4_MeetingAbstracts.s57002"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200311000-00011"},{"key":"e_1_3_2_6_2","unstructured":"Clinical and Laboratories Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing: 20th informational supplement M100-S20. CLSI Wayne PA."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.1.57"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2008.11.002"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1258\/jrsm.2008.s18002","article-title":"Identification and management of unusual pathogens in cystic fibrosis","volume":"101","author":"Elborn JS","year":"2008","unstructured":"ElbornJS. 2008. Identification and management of unusual pathogens in cystic fibrosis. J. R. Soc. Med. 101(Suppl.):S2\u2013S5.","journal-title":"J. R. Soc. Med."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1086\/320183","article-title":"Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997\u20131999)","volume":"32","author":"Gales AC","year":"2001","unstructured":"GalesAC. 2001. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997\u20131999). Clin. Infect. Dis. 32(Suppl. 2):104\u2013113.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0732-8893(02)00443-1","article-title":"Synergy of colistin with rifampicin and trimethoprim\/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia","volume":"44","author":"Giamarellos-Bourboulis EJ","year":"2002","unstructured":"Giamarellos-BourboulisEJ KarnesisL GiamarellouH. 2002. Synergy of colistin with rifampicin and trimethoprim\/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 44:259\u2013263.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis","volume":"62","author":"Goss CH","year":"2007","unstructured":"GossCH BurnsJL. 2007. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 62:360\u2013367.","journal-title":"Thorax"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2109078"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.6.1754"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0732-8893(01)00281-4","article-title":"In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations","volume":"41","author":"Krueger TS","year":"2001","unstructured":"KruegerTS ClarkEA NixDE. 2001. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn. Microbiol. Infect. Dis. 41:71\u201378.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-09"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(05)67691-X","article-title":"Combination antibiotic susceptibility testing in cystic fibrosis","volume":"366","author":"MacKenzie FM","year":"2005","unstructured":"MacKenzieFM GriffithsC DempseyO DevereauxG GouldIM. 2005. Combination antibiotic susceptibility testing in cystic fibrosis. Lancet 366:1693.","journal-title":"Lancet"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2004.03.009"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00007203"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp384"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/ppul.20671","article-title":"Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection","volume":"42","author":"Moriarty TF","year":"2007","unstructured":"MoriartyTF McElnayJC ElbornJS TunneyMM. 2007. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Paediatr. Pulmonol. 42:1008\u20131017.","journal-title":"Paediatr. Pulmonol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/GIM.0b013e31818e55a2","article-title":"Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders","volume":"10","author":"Moskowitz SM","year":"2008","unstructured":"MoskowitzSM. 2008. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet. Med. 10:851\u2013868.","journal-title":"Genet. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh128"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg301"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.diagmicrobio.2010.02.015","article-title":"In vitro synergistic\/additive activity of levofloxacin with meropenem against Stenotrophomonas maltophilia","volume":"67","author":"Pankey GA","year":"2010","unstructured":"PankeyGA AshcraftDS. 2010. In vitro synergistic\/additive activity of levofloxacin with meropenem against Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 67:297\u2013300.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/MOP.0b013e3280109b90","article-title":"Advances in cystic fibrosis therapies","volume":"18","author":"Rowe SM","year":"2006","unstructured":"RoweSM ClancyJP. 2006. Advances in cystic fibrosis therapies. Curr. Opin. Pediatr. 18:604\u2013613.","journal-title":"Curr. Opin. Pediatr."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.prrv.2007.04.006","article-title":"Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: \u2018the motion for\u2019","volume":"8","author":"Saiman L","year":"2007","unstructured":"SaimanL. 2007. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: \u2018the motion for\u2019. Paediatr. Respir. Rev. 8:249\u2013255.","journal-title":"Paediatr. Respir. Rev."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.168-171.2004"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0924-8579(02)00269-8","article-title":"In vitro activity of \u03b2-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa","volume":"21","author":"Song W","year":"2003","unstructured":"SongW WooHJ KimJS LeeKM. 2003. In vitro activity of \u03b2-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 21:8\u201312.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1581-1584.2001"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.07.008"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcf.2009.09.003","article-title":"Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy","volume":"9","author":"Zemanick ET","year":"2010","unstructured":"ZemanickET. 2010. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J. Cyst. Fibros. 9:1\u201316.","journal-title":"J. Cyst. Fibros."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00072-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00072-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:10:45Z","timestamp":1645481445000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00072-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1128\/AAC.00072-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00072-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"2012-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}